Description
SWOT ANALYSIS OF TAKEDA PHARMACEUTICALS
Takeda Pharmaceutical
Parent Company
Takeda Pharmaceutical
Category
Pharmaceutical
Sector
Health Care
Tagline/ Slogan
Transformation into a New Takeda
The largest pharmaceutical company in Japan and one of the global USP leaders of the industry
STP
Segment
Metabolic, CNS, Inflammatory diseases & oncology
Target Group
Healthcare professionals & pharmacists.
Takeda is committed to striving towards better health for patients Positioning worldwide through leading innovation in medicine.
SWOT Analysis
1. Merger with Zydus enhanced brand position 2. Profitable position as the largest drug maker in Japan and global presence in nearly 25 countries 3. Takeda effect in which sales & marketing work closely to revitalize product showing flat sales 4. Strong product pipeline and over 36,000 employees Strength 5. Good positioning in endocrinology market
1. Largely dependent on its four blockbuster therapeutics 2. Product recalls & discontinued projects have earlier affected image Weakness 3. Limited presence in emerging markets
1. It can enhance its positioning in monoclonal antibody development 2. It can enter India’s increasing generic market Opportunity 3. Increasing standards of living
Threats
1. Japanese health care reforms encouraging generic prescribing
2. Increased penetration of western players in Japanese market 3. Natural calamities in Japan
Competition
1. Abbot laboratories 2. AstraZeneca 3. Astellas Pharma Inc 4. Lupin Competitors 5. Cipla
doc_312609470.docx
SWOT ANALYSIS OF TAKEDA PHARMACEUTICALS
Takeda Pharmaceutical
Parent Company
Takeda Pharmaceutical
Category
Pharmaceutical
Sector
Health Care
Tagline/ Slogan
Transformation into a New Takeda
The largest pharmaceutical company in Japan and one of the global USP leaders of the industry
STP
Segment
Metabolic, CNS, Inflammatory diseases & oncology
Target Group
Healthcare professionals & pharmacists.
Takeda is committed to striving towards better health for patients Positioning worldwide through leading innovation in medicine.
SWOT Analysis
1. Merger with Zydus enhanced brand position 2. Profitable position as the largest drug maker in Japan and global presence in nearly 25 countries 3. Takeda effect in which sales & marketing work closely to revitalize product showing flat sales 4. Strong product pipeline and over 36,000 employees Strength 5. Good positioning in endocrinology market
1. Largely dependent on its four blockbuster therapeutics 2. Product recalls & discontinued projects have earlier affected image Weakness 3. Limited presence in emerging markets
1. It can enhance its positioning in monoclonal antibody development 2. It can enter India’s increasing generic market Opportunity 3. Increasing standards of living
Threats
1. Japanese health care reforms encouraging generic prescribing
2. Increased penetration of western players in Japanese market 3. Natural calamities in Japan
Competition
1. Abbot laboratories 2. AstraZeneca 3. Astellas Pharma Inc 4. Lupin Competitors 5. Cipla
doc_312609470.docx